Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. develops precision medicine oncology therapies for molecularly defined cancer populations. The company’s news centers on targeted small-molecule programs, synthetic lethality research, antibody-drug conjugates and biomarker-guided clinical development across solid tumors.
Recurring updates include darovasertib clinical data in uveal melanoma, including combination work with crizotinib, as well as pipeline developments for programs such as IDE849, IDE161, IDE574 and IDE397. Company announcements also cover medical-meeting presentations, FDA regulatory interactions, clinical collaboration activity, quarterly financial results, cash runway commentary and equity compensation grants under Nasdaq inducement rules.
IDEAYA Biosciences announced updates for its IDE397, a Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors. A clinical data update is anticipated for H2 2024, covering over 15 evaluable MTAP lung and bladder cancer patients, including efficacy and molecular response analyses. The company is expanding IDE397 Phase 2 monotherapy to include bladder cancer, in addition to squamous lung cancer. Over 35 clinical trial sites have been activated globally for rapid enrollment. IDE397 is also involved in a Phase 1/2 trial with Amgen’s AMG 193 and preclinical combinations.
IDEAYA Biosciences announced promising Phase 2 results for darovasertib in treating neoadjuvant uveal melanoma (UM). The study, presented at the ASCO 2024 Annual Meeting, showed a 75% eye preservation rate and a median 47% tumor shrinkage in enucleation patients. Company-sponsored trials enrolled over 40 patients, with an observed median tumor shrinkage of 72% after 4 months and high eye preservation rates. IDEAYA plans a Type C FDA meeting in H2 2024 to discuss a registrational trial. Darovasertib demonstrated a manageable safety profile, with mostly low-grade adverse events. The global annual incidence of UM is estimated at 8,000-10,000 patients.
On May 31, 2024, IDEAYA Biosciences, a precision medicine oncology company, announced the granting of non-qualified stock options to purchase 49,000 shares of its common stock to two new employees. The grants were made under the 2023 Employment Inducement Incentive Award Plan as per Nasdaq Listing Rule 5635(c)(4). The stock options, priced at $35.79 per share, match the closing price on the grant date. They have a 10-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next three years.
IDEAYA Biosciences, a precision medicine oncology company, announced its participation in two upcoming investor relations events in June 2024. The company will be represented by CEO Yujiro S. Hata at the Jefferies Global Healthcare Conference on June 5th, 2024, at 9:00 AM ET, and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10th, 2024, at 8:00 AM ET. Both events will feature fireside chats hosted by equity research analysts. Live audio webcasts of these events will be available on the IDEAYA website, with replays accessible for 30 days after the events.
IDEAYA Biosciences (NASDAQ: IDYA) has appointed Daniel A. Simon as Chief Business Officer, effective August 2024. Simon brings over 18 years of experience from top life sciences and strategy consulting firms, including his tenure at Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & Company. IDEAYA's CEO Yujiro S. Hata expressed confidence in Simon's ability to enhance the company's corporate strategy and business development. Simon aims to support IDEAYA's mission to develop a diversified pipeline focused on unmet needs in cancer, targeting biomarker-defined cancers such as GNAQ/11, MTAP-deletion, HRD, and MSI-high solid tumors.
IDEAYA Biosciences has released preliminary clinical results from a Phase 2 trial of darovasertib, an oral PKC inhibitor, as a treatment for neoadjuvant uveal melanoma. The study, involving 15 patients, demonstrated a 67% eye preservation rate in patients initially planned for enucleation.
Median tumor shrinkage was approximately 39% after six months. Darovasertib was well tolerated, with no serious drug-related adverse events reported. The full data will be presented at the ASCO 2024 Annual Meeting on June 3.
IDEAYA Biosciences announced preliminary clinical results from a Phase 2 trial of darovasertib for neoadjuvant treatment in uveal melanoma (UM) at the ASCO 2024 Annual Meeting. The study, led by Dr. Anthony Joshua, involved 15 patients planned for enucleation, treated with darovasertib 300mg twice daily. Results showed a 67% eye preservation rate and a median tumor shrinkage of approximately 45% after six months. The treatment was generally well tolerated, with no serious drug-related adverse events reported. Additional data will be presented on June 3, 2024.
IDEAYA Biosciences, Inc. reported its first-quarter 2024 financial results, highlighting progress in developing potential first-in-class clinical programs targeting various solid tumors, including GNAQ/11, MTAP-deletion, and HRD solid tumors. The company showcased positive advancements in its clinical pipeline, strategic partnerships, and a robust balance sheet with $941.4 million in cash, cash equivalents, and marketable securities as of March 31, 2024.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) will participate in the RBC Capital Markets Global Healthcare Conference on May 14th, 2024. The event will feature a fireside chat with CEO Yujiro S. Hata. The company aims to engage with investors and showcase its precision medicine oncology initiatives.
Summary not available.